Display options
Cite
He P, Niu S, Wang S, et al. Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor. Acta Pharm Sin B. 2019;9(6):1193-1203doi: 10.1016/j.apsb.2019.06.010.
He, P., Niu, S., Wang, S., Shi, X., Feng, S., Du, L., Zhang, X., Ma, Z., Yu, B., & Liu, H. (2019). Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor. Acta pharmaceutica Sinica. B, 9(6), 1193-1203. https://doi.org/10.1016/j.apsb.2019.06.010
He, Pengxing, et al. "Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor." Acta pharmaceutica Sinica. B vol. 9,6 (2019): 1193-1203. doi: https://doi.org/10.1016/j.apsb.2019.06.010
He P, Niu S, Wang S, Shi X, Feng S, Du L, Zhang X, Ma Z, Yu B, Liu H. Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor. Acta Pharm Sin B. 2019 Nov;9(6):1193-1203. doi: 10.1016/j.apsb.2019.06.010. Epub 2019 Jun 28. PMID: 31867165; PMCID: PMC6900553.
Copy Download .nbib Format: NLM
Share it on

Acta Pharm Sin B. 2019 Nov;9(6):1193-1203. doi: 10.1016/j.apsb.2019.06.010. Epub 2019 Jun 28.

Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor.

Acta pharmaceutica Sinica. B

Pengxing He, Shenghui Niu, Shuai Wang, Xiaojing Shi, Siqi Feng, Linna Du, Xuyang Zhang, Zhilu Ma, Bin Yu, Hongmin Liu

Affiliations

  1. School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
  2. State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, China.

PMID: 31867165 PMCID: PMC6900553 DOI: 10.1016/j.apsb.2019.06.010

Abstract

EGFR tyrosine kinase inhibitor (EGFR-TKI) has been used successfully in clinic for the treatment of solid tumors. In the present study, we reported the discovery of

© 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

Keywords: Antitumor activity; EGFR inhibitor; Tyrosine kinase; WS-157

References

  1. J Med Chem. 2011 Dec 8;54(23):8030-50 - PubMed
  2. Cancer Res. 2006 May 1;66(9):4802-7 - PubMed
  3. J Med Chem. 2019 Mar 14;62(5):2772-2797 - PubMed
  4. Biochem Pharmacol. 2012 Aug 1;84(3):260-7 - PubMed
  5. Bioorg Chem. 2019 Mar;84:164-169 - PubMed
  6. Bioorg Med Chem. 2013 Dec 15;21(24):7988-98 - PubMed
  7. J Pain Palliat Care Pharmacother. 2012 Jun;26(2):123-6 - PubMed
  8. Acta Pharm Sin B. 2018 Jul;8(4):563-574 - PubMed
  9. Acta Pharm Sin B. 2015 Sep;5(5):390-401 - PubMed
  10. Bioorg Med Chem Lett. 2001 Jul 23;11(14):1911-4 - PubMed
  11. Bioorg Med Chem. 2018 Oct 1;26(18):5006-5017 - PubMed
  12. Theranostics. 2018 Apr 15;8(10):2884-2895 - PubMed
  13. Biochem J. 1989 Apr 15;259(2):577-83 - PubMed
  14. N Engl J Med. 2008 Mar 13;358(11):1160-74 - PubMed
  15. Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 - PubMed
  16. Acta Pharm Sin B. 2019 Jul;9(4):794-808 - PubMed
  17. Gene. 2006 Jan 17;366(1):2-16 - PubMed
  18. Cancer Res. 1997 Nov 1;57(21):4838-48 - PubMed
  19. Curr Opin Investig Drugs. 2008 Dec;9(12):1336-46 - PubMed
  20. Drugs. 2016 Feb;76(2):263-73 - PubMed
  21. J Med Chem. 2003 Jan 2;46(1):49-63 - PubMed
  22. N Engl J Med. 2005 Feb 24;352(8):786-92 - PubMed
  23. Curr Opin Cell Biol. 2007 Apr;19(2):124-34 - PubMed
  24. Acta Pharmacol Sin. 2014 Dec;35(12):1546-55 - PubMed
  25. Clin Cancer Res. 2008 May 15;14(10):2895-9 - PubMed
  26. J Med Chem. 1999 May 20;42(10):1803-15 - PubMed
  27. J Pharm Pharmacol. 1999 Sep;51(9):1037-40 - PubMed
  28. J Med Chem. 2010 Oct 14;53(19):6934-46 - PubMed
  29. N Engl J Med. 2015 Apr 30;372(18):1700-9 - PubMed
  30. J Pharmacol Exp Ther. 2012 Nov;343(2):342-50 - PubMed
  31. Acta Pharmacol Sin. 2014 Aug;35(8):1055-64 - PubMed
  32. Cancer Biol Ther. 2009 Sep;8(17):1640-7 - PubMed
  33. J Med Chem. 2012 Dec 13;55(23):10685-99 - PubMed
  34. Lung Cancer. 2012 May;76(2):177-82 - PubMed

Publication Types